License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) ...

-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation -Initial safety ...

-Focus on programs for Wet AMD, Diabetic Retinopathy, and Duchenne Muscular Dystrophy ROCKVILLE, Md., June 27, 2023 /PRNewswire/ -- REGENXBIO Inc. (RGNX) today announced that it will host a virtual ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...

Siren plans to initiate a first-in-human clinical study in adult patients with recurrent high-grade glioma. This advancement builds on the Company’s broader Universal AAV Immuno-Gene Therapy platform, ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a leading manufacturer of genetic medicines, today announced that its manufacturing facility has successfully completed the audits necessary and ...

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product ...

ROCKVILLE, Md., June 27, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a virtual investor day on July 11, 2023. During the event, members of REGENXBIO's ...